RESUMO
Male Sprague-Dawley rats were exposed to 1,2,4-tribromobenzene (TBB) by gavage for 5 days, 2, 4, and 13 weeks at 0, 2.5, 5, 10, 25, or 75 mg/kg per d. There were no TBB exposure-related clinical signs of toxicity or changes in body weight. Liver weight increases were dose and exposure time related and statistically significant at ≥10 mg/kg per d. Incidence and severity of centrilobular cytoplasmic alteration and hepatocyte hypertrophy were dose and time related. The 75 mg/kg per d group had minimally increased mitoses within hepatocytes (5 days only). Hepatocyte vacuolation was observed (13 weeks) and was considered TBB exposure related at ≥25 mg/kg per d. Concentrations of blood TBB increased linearly with dose and at 13 weeks, ranged from 0.5 to 17 µg/mL (2.5-75 mg/kg per d). In conclusion, rats administered TBB doses of 10-75 mg/kg per d for 13 weeks had mild liver effects. A no observed adverse effect level of 5 mg/kg per d was selected based on the statistically significant incidence of hepatocyte hypertrophy at doses ≥10 mg/kg per d.
Assuntos
Bromobenzenos/toxicidade , Fígado/efeitos dos fármacos , Animais , Bromobenzenos/sangue , Bromobenzenos/farmacocinética , Fígado/patologia , Masculino , Nível de Efeito Adverso não Observado , Tamanho do Órgão/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Testes de Toxicidade SubcrônicaRESUMO
The distribution, excretion and metabolism of 1,4-dibromobenzene (1,4-DBB) and 1,2-dibromobenzene (1,2-DBB), following a single intraperitoneal administration to female Wistar rats, were investigated using radiotracer 3H and GC-MS technique. The maximum level of 3H after 1,4-DBB administration was detected in all examined rat tissues between 4 and 24 h foltowing the injection. The highest concentrations of 3H were found in fat tissue, muscles, adrenal glands and sciatic nerve. About 50% of administered dose was still retained in the rat 72 h after injection. For 1,2-DBB, the highest level of 3H was in the liver, kidneys and fat tissue 4 and 8 h after administration. Three days after injection, less than 2% of the given dose was retained in the rat body. Urine turned out to be the main route of 3H excretion following the injection of both compounds (30% and 82%, after 1,4-DBB and 1,2-DBB, respectively), and about 4% of the given dose was excreted in feces. In urine of rats the following substances were identified (in sequence 1,4-dBB and 1,2-dBB): (1) unchanged parent compounds (5 and 11%); (2) dibromophenols (84 and 73%); (3) dibromothiophenols (5 and 10%) and (4) monobromophenols (1.9 and 0.7%). This study suggests that 1,2-DBB is characterized by a relatively high turnover rate, whereas 1,4-DBB shows a tendency for long-term retention in the body.
Assuntos
Bromobenzenos/farmacocinética , Animais , Bromobenzenos/sangue , Bromobenzenos/urina , Cromatografia Gasosa , Feminino , Polônia , Ratos , Ratos Wistar , Distribuição TecidualRESUMO
The distribution, excretion and metabolism of 1,3-dibromobenzene following a single i.p. administration to rats 100 or 300 mg/kg was investigated using radiotracer [3H] and GC-MS technique. After 72 hours about 74 to 90% were excreted in urine. The highest radioactivity was observed in the liver, kidneys and fat tissue. Later on a steady decline of radioactivity was apparent in all investigated tissues except for blood cells and the sciatic nerve, where constant levels were noted. In urine the following substances were identified and quantified by GC peak areas: unchanged 1,3-DBB (18%), dibromophenols (34%), dibromothiophenols (28%), dibromothioanisole (1.8%), bromophenol (5.5%), bromohydroxythiophenols (5%), and bromohydroxythioanisole (7.5%).
Assuntos
Bromobenzenos/metabolismo , Bromobenzenos/farmacocinética , Poluentes Ambientais/metabolismo , Poluentes Ambientais/farmacocinética , Absorção , Animais , Biotransformação , Bromobenzenos/sangue , Bromobenzenos/urina , Relação Dose-Resposta a Droga , Poluentes Ambientais/sangue , Poluentes Ambientais/urina , Fezes/química , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Injeções Intraperitoneais , Ratos , Ratos Wistar , Distribuição Tecidual , TrítioRESUMO
AIM: The analgesic efficacy and safety of single oral doses of two centrally acting compounds, the combination of 50 mg tilidine and 4 mg naloxone (Valoron N) and 50 mg tramadol (Tramal), were compared to 25, 50 and 75 mg of the non-steroidal antiinflammatory bromfenac in experimental pain. SUBJECTS AND METHODS: It was a placebo-controlled double-blind 6-way crossover study design with 12 human volunteers. Acute pain was generated by electrical tooth pulp stimulation. Treatment effects were determined by recording somatosensory-evoked potentials and by subjective pain rating. RESULTS: The tilidine/naloxone combination clearly was the most potent medication in this study, followed by bromfenac 75 mg, which produced an early pain relief. Tramadol produced poor analgesia, as did bromfenac 25 and 50 mg. There was no dose-response relationship for bromfenac. Control of plasma levels revealed pronounced interindividual differences in peak plasma concentrations for bromfenac, but not for tramadol. Tilidine/naloxone exerted adverse effects in 9, tramadol in 3 volunteers. Under medication with 25 and 50 mg bromfenac, respectively, only one subject reported adverse effects. No adverse effects were experienced with 75 mg bromfenac or placebo. CONCLUSION: The results support previous conclusions about the analgesic efficacy of tilidine/naloxone and tramadol in experimental pain. Moreover, the findings suggest that 75 mg bromfenac might be suitable for fast but short relief of pain of non-inflammatory genesis.
Assuntos
Analgésicos/uso terapêutico , Benzofenonas/uso terapêutico , Bromobenzenos/uso terapêutico , Naloxona/uso terapêutico , Dor/tratamento farmacológico , Tilidina/uso terapêutico , Tramadol/uso terapêutico , Adulto , Analgésicos/efeitos adversos , Analgésicos/sangue , Analgésicos/farmacocinética , Área Sob a Curva , Benzofenonas/efeitos adversos , Benzofenonas/sangue , Benzofenonas/farmacocinética , Bromobenzenos/efeitos adversos , Bromobenzenos/sangue , Bromobenzenos/farmacocinética , Estudos Cross-Over , Relação Dose-Resposta a Droga , Método Duplo-Cego , Combinação de Medicamentos , Quimioterapia Combinada , Potenciais Somatossensoriais Evocados/efeitos dos fármacos , Feminino , Humanos , Masculino , Naloxona/efeitos adversos , Naloxona/sangue , Naloxona/farmacocinética , Dor/sangue , Dor/etiologia , Dor/metabolismo , Tilidina/efeitos adversos , Tilidina/sangue , Tilidina/farmacocinética , Tramadol/efeitos adversos , Tramadol/sangue , Tramadol/farmacocinéticaRESUMO
The metabolic disposition of 14C-bromfenac, an orally active, potent, nonsteroidal, nonnarcotic, analgesic agent was investigated in six healthy male subjects after a single oral 50-mg dose. The absorption of radioactivity was rapid, producing a mean maximum plasma concentration (Cmax) of 4.9 +/- 1.8 microg x equiv/mL, which was reached 1.0 +/- 0.5 hours after administration. Unchanged drug was the major component found in plasma, and no major metabolites were detected in the plasma. Total radioactivity recovered over a 4-day period from four of the six subjects averaged 82.5% and 13.2% of the dose in the urine and feces, respectively. Excretion into urine was rapid; most of the radioactivity was excreted during the first 8 hours. Five radioactive chromatographic peaks, a cyclic amide and four polar metabolites, were detected in 0- to 24-hour urine samples. Similarity of metabolite profiles between humans and cynomolgus monkeys permitted use of this animal model to generate samples after a high dose for structure elucidation. Liquid chromatography/mass spectrometry (LC/MS) analysis of monkey urine samples indicated that the four polar metabolites were two pairs of diastereoisomeric glucuronides whose molecular weight differed by two daltons. Enzyme hydrolysis, cochromatography, and LC/MS experiments resulted in the identification of a hydroxylated cyclic amide as one of the aglycones, which formed a pair of diastereoisomeric glucuronides after conjugation. Data also suggested that a dihydroxycyclic amide formed by the reduction of the ketone group that joins the phenyl rings formed the second pair of diastereoisomeric glucuronides. Further, incubation of various reference standards in control (blank) urine and buffer with and without creatinine indicated that the hydroxy cyclic amide released from enzyme hydrolysis can undergo ex vivo transformations to a condensation product between creatinine and an alpha-keto acid derivative of the hydroxy cyclic amide that is formed by oxidation and ring opening. Further experiments with a dihydroxylated cyclic amide after reduction of the keto function indicated that it too can form a creatinine conjugate.
Assuntos
Analgésicos/farmacocinética , Benzofenonas/farmacocinética , Bromobenzenos/farmacocinética , Adolescente , Adulto , Analgésicos/sangue , Animais , Área Sob a Curva , Benzofenonas/sangue , Bromobenzenos/sangue , Cromatografia Líquida de Alta Pressão , Cromatografia Líquida , Creatinina/urina , Glucuronatos/metabolismo , Meia-Vida , Humanos , Macaca fascicularis , Masculino , Espectrometria de Massas , Distribuição TecidualRESUMO
The pharmacokinetic profile of bromfenac (2-amino-3-(4-bromobenzoyl) benzeneacetic acid, CAS91714-93-1) has been investigated in 12 healthy subjects (6 male and 6 female) after single oral doses of 25, 50 and 75 mg. Plasma concentrations were determined by a sensitive HPLC method with spectrophotometric detection. Sampling was performed up to 300 min after drug ingestion. Linear pharmacokinetics could be verified for this dose-range; there was a clear, positive dose-plasma concentration relationship. Bromfenac exhibits a cmax of 3.49 +/- 1.65-8.81 +/- 3.45 micrograms/ml at tmax 52 +/- 27-42 +/- 15 min. The elimination half-life was 39.8 +/- 7.3-34.2 +/- 8.0 min with a clearance (Cl/f) of 120.6 +/- 51.6-135.3 +/- 34.6 ml/min and a volume of distribution (Vd/f) 6.82 +/- 2.88-6.64 +/- 2.29 l. The results obtained show a fast absorption and rapid elimination of bromfenac when administered orally. The short plasma half-life of bromfenac apparently presents no direct relationship to its clinical effectiveness.
Assuntos
Analgésicos/farmacocinética , Benzofenonas/farmacocinética , Bromobenzenos/farmacocinética , Administração Oral , Adulto , Analgésicos/administração & dosagem , Analgésicos/sangue , Anti-Inflamatórios não Esteroides/farmacocinética , Benzofenonas/administração & dosagem , Benzofenonas/sangue , Bromobenzenos/administração & dosagem , Bromobenzenos/sangue , Cromatografia Líquida de Alta Pressão , Feminino , Meia-Vida , Humanos , Masculino , Espectrofotometria UltravioletaRESUMO
In a dynamic inhalation system, mice, rats and rabbits were exposed to bromobenzene vapour (250-3400 p.p.m.) for 4 hr. Blood concentrations of bromobenzene were determined by head-space gas chromatography. After inhalation of 1000 p.p.m. for 4 hr, concentrations of 153, 102 and 47 micrograms bromobenzene/ml blood were found in mice, rats and rabbits, respectively. In vitro experiments showed a blood/air partition coefficient at 37 degrees of approximately 200, which was reflected by a linear uptake of bromobenzene up to an air concentration of 2500 p.p.m. Compared with results obtained previously by intraperitoneal bromobenzene administration inhalation resulted in higher blood concentrations.
Assuntos
Bromobenzenos/farmacocinética , Absorção , Administração por Inalação , Animais , Bromobenzenos/administração & dosagem , Bromobenzenos/sangue , Cromatografia Gasosa/métodos , Masculino , Camundongos , Coelhos , Ratos , Ratos Endogâmicos , Fatores de TempoRESUMO
Bromfenac [2-amino-3-(4-bromobenzoyl)benzenacetic acid, sodium salt sesquihydrate] exhibited potent analgesic and anti-inflammatory activity in mice and rats. In a mouse model of pain (acetylcholine abdominal constriction), bromfenac showed a rapid onset of activity (20 min) that persisted for at least 4 hr. In a rat model of inflammation (carrageenan foot edema), a single oral dose of bromfenac, 0.316 mg/kg, produced significant anti-inflammatory activity up to 24 hr after dosing. Bromfenac was readily absorbed after oral administration, peak plasma levels being achieved at the earliest time tested: 20 min in the mouse and 30 min in the rat. The plasma half-life of bromfenac in rats is less than 4 hr. Since the anti-inflammatory activity persisted for 20 to 24 hr in spite of its short plasma half-life, it appears that there is no direct correlation between duration of activity and plasma drug level.
Assuntos
Analgésicos/farmacologia , Anti-Inflamatórios não Esteroides/farmacologia , Benzofenonas/farmacologia , Bromobenzenos/farmacologia , Analgesia , Analgésicos/sangue , Animais , Anti-Inflamatórios não Esteroides/sangue , Benzofenonas/sangue , Bromobenzenos/sangue , Feminino , Meia-Vida , Camundongos , Camundongos Endogâmicos ICRRESUMO
A previous study has revealed that phentolamine markedly antagonizes the bromobenzene-induced hepatotoxicity and lethality in B6C3F1 mice. One potential mechanism by which phentolamine may diminish the bromobenzene-induced hepatotoxicity is by a direct or indirect interference with the metabolism of bromobenzene to toxic metabolites. In the present study, phentolamine cotreatment failed to alter the elimination of bromobenzene from serum or the distribution of bromobenzene to liver. This suggests that phentolamine cotreatment does not indirectly interfere with bromobenzene bioactivation secondary to changes in bromobenzene absorption, distribution, or elimination. Further, a phentolamine concentration 10- to 20-fold greater than those measured in vivo failed to alter the in vitro metabolism of bromobenzene to its ortho- and para-phenolic metabolites. It is believed that para-bromophenol represents the rearrangement product of the hepatotoxic 3,4-epoxide and that ortho-bromophenol is a product of the nonhepatotoxic 2,3-epoxide pathway. Thus, it appears that phentolamine does not antagonize bromobenzene-induced hepatotoxicity by inhibiting the formation of hepatotoxic intermediates, nor by enhancing metabolism via the nonhepatotoxic pathway. On the basis of these studies, we conclude that phentolamine antagonism of bromobenzene-induced hepatotoxicity occurs through a mechanism independent of bromobenzene bioactivation.
Assuntos
Bromobenzenos/antagonistas & inibidores , Hepatopatias/prevenção & controle , Fentolamina/farmacologia , Antagonistas Adrenérgicos alfa/farmacologia , Animais , Biotransformação/efeitos dos fármacos , Bromobenzenos/sangue , Bromobenzenos/metabolismo , Doença Hepática Induzida por Substâncias e Drogas , Técnicas In Vitro , Fígado/metabolismo , Hepatopatias/metabolismo , Masculino , Camundongos , Microssomos Hepáticos/metabolismo , Fentolamina/sangue , Fentolamina/metabolismoRESUMO
Our studies of bromobenzene metabolism have shown that the 3,4-oxide is metabolized to 3- and 4-bromophenol through an extended glutathione pathway. The mechanism of sulfur elimination from a dihydrobromobenzene metabolite is not known, although it is known that the aromatization reaction will occur in a 9000-g supernatant fraction of rat liver. The hepatotoxic and nephrotoxic metabolites of bromobenzene are most likely bromthiocatechols and a bromothiopyrogallol, respectively.
Assuntos
Bromobenzenos/metabolismo , Animais , Biotransformação , Bromobenzenos/sangue , Bromobenzenos/urina , Fenômenos Químicos , Doença Hepática Induzida por Substâncias e Drogas/metabolismo , Química , Cromatografia Gasosa , Cromatografia Gasosa-Espectrometria de Massas , Cobaias , Nefropatias/induzido quimicamente , Nefropatias/metabolismo , Oxirredução , Fenóis/metabolismo , Ratos , Especificidade da EspécieRESUMO
The effects of sodium selenite (12.5 or 30 mumol/kg, ip) upon bromobenzene metabolism were examined in male rats treated with selenite at 72 hr prior to bromobenzene exposure (7.5 mmol/kg, ip). The inhibitory nature of selenium treatment upon xenobiotic metabolism and increased production of hepatic thiol suggested that selenite might affect metabolic activation and detoxification of bromobenzene. Selenite treatment lowered in vivo covalent binding of [14C]bromobenzene while the in vitro covalent binding of [14C]bromobenzene in microsomes isolated from selenite-treated rats was unaffected compared to control. When the rate of [14C]bromobenzene decline in whole blood was evaluated in selenite-treated rats over 48 hr after bromobenzene administration, no significant differences were observed when compared to control. Furthermore, values of glutathione conjugates and hydroxylated metabolites of bromobenzene were similar in urine samples collected over 48 hr from selenite and control rats. Mechanistically, reduction of bromobenzene hepatotoxicity by selenite is not mediated through an altered metabolism of bromobenzene, but by alteration of cellular events occurring after metabolic activation.
Assuntos
Bromobenzenos/metabolismo , Fígado/efeitos dos fármacos , Selênio/farmacologia , Animais , Bromobenzenos/sangue , Bromobenzenos/urina , Radioisótopos de Carbono , Interações Medicamentosas , Meia-Vida , Injeções Intraperitoneais , Cinética , Fígado/metabolismo , Masculino , Ratos , Ratos Endogâmicos , Ácido SeleniosoRESUMO
The in vivo binding of the radiobrominated neuroleptic brombenperidol in rat brain was studied. The accumulation of the radiolabeled neuroleptic was high in the striatum and relatively low in the cerebellum, cortex, and blood. Striatal binding of brombenperidol was saturable and displaced by subsequent administration of benperidol. The rationale for the development of 75Br-brombenperidol as a radiopharmaceutical for the non-invasive imaging of cerebral dopamine receptor areas is presented.
Assuntos
Bemperidol/análogos & derivados , Encéfalo/metabolismo , Bromobenzenos/metabolismo , Receptores Dopaminérgicos/metabolismo , Animais , Ligação Competitiva , Bromo , Bromobenzenos/sangue , Cerebelo/metabolismo , Córtex Cerebral/metabolismo , Corpo Estriado/metabolismo , Feminino , Marcação por Isótopo , Radioisótopos , Ensaio Radioligante , Ratos , Ratos EndogâmicosRESUMO
Bromobenzene-3,4-oxide can be detected in venous blood of rats by trapping it as the corresponding 35[S]glutathione conjugates. More bromobenzene-3,4-oxide is detected in venous blood of rats treated with phenobarbital and diethyl maleate than in venous blood of rats treated with phenobarbital alone. The half-life of bromobenzene-3,4-oxide in venous blood was about 13.5 s. Bromobenzene-3,4-oxide may contribute to the extrahepatic covalent binding and presumably the toxicity observed after bromobenzene administration. The present technique may be used to determine in blood, the presence or absence of other reactive metabolites that form glutathione conjugates.
Assuntos
Bromobenzenos/sangue , Animais , Bromobenzenos/toxicidade , Meia-Vida , Masculino , Maleatos/farmacologia , Fenobarbital/farmacologia , Ratos , Ratos EndogâmicosRESUMO
A method is described for the quantitation of new non-tricyclic antidepressant, zimelidine, and its pharmacologically active, N-demethylated metabolite, norzimelidine, in plasma. The method involves a single extraction of basified plasma with diethyl ether, concentration of the ethereal extract, chromatography on a high-performance liquid chromatograph and quantitation using a variable-wavelength UV detector. The respective geometric isomers of zimelidene and norzimelidine are used as internal standards for quantitation. Resolution is effected using a 5-micron silica gel column with an aqueous methanolic solution of ammonium nitrate as the mobile phase. The minimum quantitated amount was 25 ng and the coefficient of variation for the method did not exceed 7% in the range 25 to 1000 ng/ml for both compounds. The method has been applied in monitoring the plasma concentration of zimelidine and norzimelidine in plasma from depressed patients and an example of this application is presented.
Assuntos
Antidepressivos/sangue , Bromobenzenos/sangue , Piridinas/sangue , Cromatografia Líquida de Alta Pressão , Humanos , Isomerismo , Zimeldina/análogos & derivadosRESUMO
Dimethylformamide dialkylacetals have been found to react readily with primary sulfonamides to form N-dimethylaminomethylene derivatives. These compounds possess excellent gas-liquid chromatographic properties and can be conveniently prepared at the submicrogram level. Their retention times are much greater than those of other sulfonamide derivatives (e.g., N,N-dimethyl) but their ease of preparation and lack of absorptive properties make them attractive for gas-liquid chromatographic studies. The practical applicability of this derivatization approach to biological studies is illustrated by the gas-liquid chromatographic determination of 3-bromo-5-cyanobenzenesulfonamide in ovine blood using 3,5-dibromobenzenesulfonamide as the internal standard. The method has a detection limit of 25 ppb with electron capture detection.